Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 20/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 16/20 | 0.54 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.47 |
| ▸ | TP53BP1 | Q12888 | 5/20 | 0.42 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30299323 | 0.83 | NPY2R (0.41) | L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL30299294 | 0.82 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1MBTD1TP53BP1 | |
| SCHEMBL30299305 | 0.82 | ALDH1A1 (0.38) | L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL29929683 | 0.82 | AXL (0.40) | L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL30299383 | 0.82 | HRH3 (0.37) | L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL30299390 | 0.81 | PDCD1 (0.38) | L3MBTL3L3MBTL1 | |
| SCHEMBL29928123 | 0.81 | AXL (0.39) | L3MBTL3L3MBTL1 | |
| SCHEMBL30299344 | 0.81 | L3MBTL3 (0.59) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL30299348 | 0.80 | GPR4 (0.42) | — | |
| SCHEMBL29928107 | 0.78 | MAPT (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116075303-A | Method of selecting patients treated with a combination of an AXL inhibitor and an immune checkpoint modulator | 卑尔根生物股份公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115916344-A | AXL inhibitors for antiviral therapy | 卑尔根生物股份公司 | 2023-04-04 | — | — | CN | disclosed |